Kringle Pharma,Inc.
4884クリングルファーマ株式会社
Latest half-year results
First half · fiscal year to 2026-09 · filed 2026-05-11For the first half of the fiscal year to 2026-09: Revenue ¥0 billion (+2.2% YoY), Ordinary income ¥-0.5 billion, Net income ¥-0.5 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥37m | +2.2% |
| Ordinary profit | −¥514m | — |
| Net profit to owners | −¥517m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4884/earnings-releases.
Financials
Japan GAAP · non-consolidated · fiscal year to 2025-09-30- Revenue
- ¥72m
- Net income
- −¥916m
- ROE
- —
- Equity ratio
- 61.5%
- Dividend / share
- —
- Employees
- 17
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | ¥72m | −¥916m | ¥2,079m | ¥1,309m | — | ¥-133.92 | −¥756m |
| 2024-09-30 | ¥80m | −¥756m | ¥2,757m | ¥2,108m | — | ¥-118.21 | −¥661m |
| 2023-09-30 | ¥69m | −¥854m | ¥2,619m | ¥2,022m | — | ¥-158.46 | −¥689m |
| 2022-09-30 | ¥392m | −¥332m | ¥3,209m | ¥2,789m | — | ¥-68.33 | ¥16m |
| 2021-09-30 | ¥290m | −¥301m | ¥2,636m | ¥2,506m | — | ¥-72.51 | −¥561m |
Indicators
Computed by us from filings · fiscal year to 2025-09-30| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | -12.6671 | 0.3 |
| Equity ratio, % | 61.5 | 60.9 |
| Revenue growth | -0.0977 | 6.7 |
| Net income growth | -0.2113 | 22.3 |
| Operating cash flow / assets | -0.3635 | 1.3 |
Results wording balance: +1.00. Proprietary text method; it describes the wording only and does not interpret context.
Via /v1/companies/4884/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4884/votingOwnership changes
All companies →- 2026-08-27
Evo Fund cut holdings in Kringle Pharma,Inc. (4884) to 4.79% from 6.01%, below the 5% threshold.
- 2026-06-05
Evo Fund reduced holdings in Kringle Pharma,Inc. (4884) to 6.01% from 6.17%.
- 2026-05-29
Evo Fund reduced holdings in Kringle Pharma,Inc. (4884) to 6.17% from 7.39%.
- 2026-05-25
Evo Fund reduced holdings in Kringle Pharma,Inc. (4884) to 7.39% from 8.45%.
- 2026-05-25
Evo Fund filed a correction to a 5% report on Kringle Pharma,Inc. (4884).
- 2026-05-20
Evo Fund reduced holdings in Kringle Pharma,Inc. (4884) to 8.45% from 9.02%.
- 2026-04-09
Evo Fund reduced holdings in Kringle Pharma,Inc. (4884) to 9.02% from 12.46%.
- 2026-04-09
Holdings of Evo Fund in Kringle Pharma,Inc. (4884) moved below 10% (12.46% -> 9.02%).
- 2026-04-08
Evo Fund reduced holdings in Kringle Pharma,Inc. (4884) to 12.46% from 15.35%.
- 2026-03-18
Evo Fund reduced holdings in Kringle Pharma,Inc. (4884) to 15.35% from 16.21%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Evo Fund | 2025-07-16 – 2026-08-20 | +111,700 | +1.42pt | ¥485.95 | ¥424–510 |
| Evolution Capital Management LLC | 2025-07-16 – 2026-08-20 | +88,800 | +1.15pt | ¥485.95 | ¥424–510 |
| 東北大学ベンチャーパートナーズ株式会社 | 2024-06-25 – 2024-06-25 | -10,000 | −0.15pt | — | — |
| Barclays Capital Securities Ltd. | 2021-10-25 – 2023-12-20 | 0 | −0.05pt | ¥746.2 | ¥612–1,013 |
| Barclays Bank PLC | 2021-10-29 – 2023-12-20 | +1,062,300 | +17.19pt | ¥662.27 | ¥618–755 |
| バークレイズ証券株式会社 | 2023-09-22 – 2023-12-20 | 0 | 0.00pt | — | — |
| Palomino Limited | 2023-07-21 – 2023-09-21 | -17,200 | −0.26pt | — | — |
| 株式会社慶應イノベーション・イニシアティブ | 2023-02-22 – 2023-03-06 | -229,700 | −4.27pt | — | — |
| DBJキャピタル株式会社 | 2023-02-16 – 2023-02-21 | -54,600 | −1.01pt | — | — |
| 東北大学ベンチャーパートナーズ株式会社 | 2020-12-28 – 2020-12-28 | -8,000 | −0.19pt | — | — |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4884/trades.
5% filings
Large shareholding reports on 4884| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-08-27 | Evo Fund | 4.79% | −1.22pt | pure investment |
| 2026-06-05 | Evo Fund | 6.01% | −0.16pt | pure investment |
| 2026-05-29 | Evo Fund | 6.17% | −1.22pt | pure investment |
| 2026-05-25 | Evo Fund | 7.39% | −1.06pt | pure investment |
| 2026-05-25 | Evo Fund | 8.45% | −0.57pt | pure investment |
| 2026-05-20 | Evo Fund | 8.45% | −0.57pt | pure investment |
| 2026-04-09 | Evo Fund | 9.02% | −3.44pt | pure investment |
| 2026-04-08 | Evo Fund | 12.46% | −2.89pt | pure investment |
| 2026-03-18 | Evo Fund | 15.35% | −0.86pt | pure investment |
| 2025-12-03 | Evo Fund | 16.21% | −1.02pt | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- — issues
- Book value
- —
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 0
- Held by listed cos.
- 4
Held by: CYBERDYNE Inc. 7779, ReproCELL Incorporated 4978, TOHO HOLDINGS CO.,LTD. 8129, M3, Inc. 2413
Purposes, all holdings and mutual flags via /v1/companies/4884/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2025-09-30| Shareholder | Shares | Ratio |
|---|---|---|
| 日本全薬工業株式会社 | 500,840 | 7.14% |
| STATE STREET BANK AND TRUST COMPANY 510643 | 246,700 | 3.52% |
| CYBERDYNE株式会社 | 200,000 | 2.85% |
| individual holder | 177,000 | 2.52% |
| 野村證券株式会社 | 122,050 | 1.74% |
| individual holder | 120,300 | 1.71% |
| 上田八木短資株式会社 | 111,800 | 1.59% |
| 丸石製薬株式会社 | 100,000 | 1.42% |
| 株式会社リプロセル | 100,000 | 1.42% |
| individual holder | 93,400 | 1.33% |
Get this as JSON
GET /v1/companies/4884
GET /v1/companies/4884/financials
GET /v1/companies/4884/details
GET /v1/companies/4884/segments
GET /v1/companies/4884/voting
GET /v1/companies/4884/tender-offers
GET /v1/companies/4884/indicators
GET /v1/companies/4884/earnings-releases
GET /v1/events?ticker=4884
GET /v1/companies/4884/trades
GET /v1/companies/4884/cross-holdings
GET /v1/companies/4884/brief